$54.06
▲ +0.1% Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline
Analyst Report: Ionis Pharmaceuticals, Inc.
Ionis to hold second quarter 2026 financial results webcast
Overview
52-week range
$35
$87
37% of range
Avg surprise (last 2)
+378.1%
Avg reaction (last 1)
+3.0%
100% positive
Latest IV / EM
51%
EM ±11.7% · $55 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.56 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.80 | — | — | — | — | financials |
| Wed Jul 30, 2025 | Jun/2025 | $0.70 | $-0.11 | +736.4% | — | — | earnings |
| Wed Apr 30, 2025 | Mar/2025 | $-0.93 | $-1.16 | +19.8% | — | +3.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.95 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.45 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.98 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.03 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.60 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Jul 29, 2026 | Jun/2026 | BMO | -$1.11 | $0.70 | -258.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $3M | — | $2M | $4M | $1M | — | $1M | $4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-117M | — | $-160M | $140M | $-147M | — | $-149M | $-66M |
| Net income | $-93M | — | $-129M | $124M | $-147M | — | $-140M | $-66M |
| EPS (diluted) | $-0.56 | — | $-0.80 | $0.70 | $-0.93 | — | $-0.95 | $-0.45 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $173M | $372M | $338M | $297M | $264M | $242M | $335M | $294M |
| Inventory | $6M | $10M | $10M | $8M | $12M | $13M | $28M | $29M |
| Total current assets | $2.94B | $2.99B | $2.52B | $2.58B | $2.42B | $2.62B | $2.71B | $2.33B |
| Total assets | $3.45B | $3.52B | $3.03B | $2.99B | $2.81B | $3.00B | $3.08B | $2.69B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $2.96B | $3.03B | $2.42B | $2.35B | $2.34B | $2.42B | $2.42B | $2.43B |
| Total equity | $491M | $489M | $618M | $632M | $476M | $588M | $662M | $264M |